Breaking Canadian GLP-1 news
GLP-1 News — Page 8
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Health Canada Reviewing GLP-1 Aspiration Pneumonia Anesthesia Risk
Health Canada opened a safety review of GLP-1 receptor agonists for aspiration pneumonia risk during general anesthesia or deep sedation, records show.
Alberta Blue Cross Flags MASH, Sleep Apnea as Next GLP-1 Uses
Alberta Blue Cross's 2026 pipeline report says GLP-1 uses may expand to MASH and obstructive sleep apnea, keeping plan spend high despite mid-2026 generics.
Lilly Sets $50 US Medicare Price for Zepbound as Canada Awaits
Eli Lilly announces $50 monthly Medicare pricing for Zepbound in US starting April 2026, while Canadian patients await Health Canada decisions on coverage.
Apotex Wins Tentative FDA Approval for Generic Ozempic
Canadian generic manufacturer Apotex receives tentative FDA approval for generic semaglutide while Health Canada reviews nine generic applications.
pCPA Sets Tiered Pricing Framework for Generic Semaglutide
Pan-Canadian Pharmaceutical Alliance establishes structured pricing tiers for generic semaglutide medications entering Canadian market mid-2026.
Ozempic Drives 8.5% of Canada's Public Drug Cost Growth
New data shows Ozempic has become Canada's largest publicly funded single-drug cost driver, representing 8.5% of total public drug spending growth.
Health Canada Approves Rybelsus for Heart Disease Prevention
Health Canada grants new indication for Rybelsus oral semaglutide tablet to reduce cardiovascular risks in adults with Type 2 diabetes and heart disease.
South African Aspen Pharmacare Targets Canada Entry Q3 2026
South African pharmaceutical giant Aspen Pharmacare aims to launch generic semaglutide in Canada by third quarter 2026 as reference market for emerging regions.
Novo Nordisk Cuts Wegovy to $149 Monthly Ahead of Generics
Novo Nordisk launches $149 monthly Wegovy pricing through August 2026 as company prepares for generic semaglutide competition in Canadian market.
Canadian Pharmacies Report GLP-1 Prices Range $300-570 Monthly
Current pharmacy pricing data shows Ozempic and Wegovy costs vary significantly across Canadian provinces, with monthly supplies ranging from $300 to $570 CAD.
Dr. Reddy's Generic Semaglutide Under Health Canada Review Since 2024
India-based pharmaceutical company Dr. Reddy's Laboratories submitted generic semaglutide application to Health Canada in early 2024, currently under review.
Canadian Semaglutide Sales Hit $3.5 Billion in 2025
IQVIA Canada reports total semaglutide sales including Ozempic and Wegovy reached $3.5 billion in 2025, highlighting market size before generic competition.
CMA Advises Patients Generic GLP-1s Coming Mid-2026
Canadian Medical Association tells patients generic GLP-1 medications expected around mid-2026, not immediately after patent expiry in January.
Health Canada Adds Submission Class Data to Drug Review Tracker
Health Canada's drug review tracker now shows submission class information as of March 20, 2026, providing more transparency for generic approvals.
Health Canada Approves New Novo Nordisk Semaglutide Brand Names
Health Canada approves new brand names for Novo Nordisk semaglutide products as company prepares for generic competition entering Canadian market.
Aspen Pharmacare Targets Q3 2026 Generic Semaglutide Launch
South African pharmaceutical giant Aspen Pharmacare plans to enter Canadian market with generic semaglutide by third quarter 2026, using Canada as reference.
WHO Conditionally Recommends GLP-1 Therapies for Obesity Treatment
World Health Organization issues conditional recommendation for GLP-1 therapies in obesity treatment, marking significant shift in global health policy approach.
Generic GLP-1 Medications Expected on Canadian Shelves This Summer
National Post reports generic semaglutide products could reach Canadian pharmacy shelves by summer 2026 as Health Canada reviews nine applications.
Study: Generic Semaglutide Production Costs Just $3 Monthly
New research reveals generic semaglutide manufacturing costs could drop to $3 per month in Canada, representing massive savings from current $400 prices.
Health Canada Eyes Summer 2026 Generic Semaglutide Approvals
Radio-Canada International reports Health Canada reviewing nine generic semaglutide submissions with summer 2026 approval timeline expectations for Canadian patients.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada